BRCC36抗体;BRCC36 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of BRCC36 in rat Brain, C6, 3T3, Hela lysates using BRCC36 antibody.    

  
  

BRCC36 (BRCA1/BRCA2-containing complex subunit 36) is a deubiquitinating enzyme (DUB) belonging to the JAMM/MPN+ metalloprotease family. It plays a critical role in regulating protein degradation and cellular signaling by removing ubiquitin chains from target proteins. BRCC36 is a core component of two distinct macromolecular complexes: the BRISC complex (BRCC36 isopeptidase complex) and the BRCA1-A complex. The BRISC complex, involved in inflammatory responses, modulates interferon signaling by stabilizing type I interferon receptors. In contrast, the BRCA1-A complex participates in DNA damage repair by regulating BRCA1 function through deubiquitination of γH2AX and other substrates.

Dysregulation of BRCC36 has been implicated in multiple diseases. Overexpression or mutations in BRCC36 are linked to cancer progression (e.g., breast and ovarian cancers), autoimmune disorders (e.g., lupus), and neurodegenerative conditions (e.g., Alzheimer’s disease). Its role in modulating NF-κB signaling and cell cycle checkpoints highlights its therapeutic potential.

BRCC36 antibodies are essential tools for studying its expression, localization, and interaction partners. They are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to explore BRCC36’s regulatory mechanisms in physiological and pathological contexts. These antibodies also aid in evaluating BRCC36 as a biomarker or therapeutic target, particularly in cancers with defective DNA repair pathways. Research utilizing BRCC36 antibodies continues to uncover its multifaceted roles in cellular homeostasis and disease pathogenesis.